|
Company:
|
AGENUS INC (AGEN)
|
|
Form Type:
|
4
|
|
Filing Date:
|
3/20/2017
|
|
CIK:
|
0001098972
|
|
Address:
|
3 FORBES ROAD
|
|
City, State, Zip:
|
LEXINGTON, Massachusetts 02421
|
|
Telephone:
|
781-674-4410
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$5.26
|
Change:
0.12 (2.34%)
|
Trade Time:
Jul 26
|
Market Cap:
$521.37M
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical-stage immuno-oncology ("I-O") company focused on the discovery
and development of therapies that engage the body's immune system to fight
cancer. Our approach to cancer immunotherapy involves a diverse portfolio
consisting of antibody-based therapeutics, adjuvants and cancer vaccine
platforms. We, in collaboration with our partners, have developed a number of
immuno-modulatory antibodies against important nodes of immune regulation. These
include antibodies targeting CTLA-4, GITR and OX40 that are in clinical
development, and our anti-PD-1 antibody anticipated to enter the clinic in the
first half of 2017. Our discovery pipeline includes a number of proprietary
checkpoint modulating ("CPM") antibodies against innovative targets such as
TIGIT and 4-1BB (also known as CD137). We believe that tailored combination
therapies are essential to combat some of the most resistant cancers.
|
|
|
|